These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 2989070)

  • 21. Tamoxifen does not improve overall survival in people with advanced-stage hepatocellular carcinoma.
    Chow PK
    Cancer Treat Rev; 2005 Oct; 31(6):491-5. PubMed ID: 16214294
    [No Abstract]   [Full Text] [Related]  

  • 22. [Study of estrogen receptors in hepatocellular carcinoma and its response to anti-estrogen therapy].
    Zheng T; Zhang Q; Xie Z
    Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):451-3. PubMed ID: 10920881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II evaluation of doxorubicin plus amiodarone in advanced hepatocarcinoma.
    Chauffert B; Seitz JF; Bedenne L; Renard P; Conroy T; Rougier P
    Gastroenterol Clin Biol; 1991; 15(10):774-5. PubMed ID: 1667769
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of elderly patients with hepatocellular carcinomas with mitomycin C and 5-fluorouracil].
    Fujii M; Murakami N; Matsuka Y; Ejiri T; Asano K
    Gan To Kagaku Ryoho; 1982 Oct; 9(10):1797-800. PubMed ID: 6307175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Tamoxifen and hepatocarcinoma].
    Mondragón Sánchez R
    Rev Gastroenterol Mex; 1998; 63(3):169. PubMed ID: 10068765
    [No Abstract]   [Full Text] [Related]  

  • 26. [The effect and pharmacokinetics of etoposide in patients with primary hepatocellular carcinoma].
    Funakoshi S; Aiba K; Dobashi F; Inamoto Y; Hirano A; Tada N; Ogihara A; Fujii T; Kuraishi Y; Yamada T
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):165-7. PubMed ID: 8380686
    [No Abstract]   [Full Text] [Related]  

  • 27. Type of estrogen receptor determines response to antiestrogen therapy.
    Villa E; Dugani A; Fantoni E; Camellini L; Buttafoco P; Grottola A; Pompei G; De Santis M; Ferrari A; Manenti F
    Cancer Res; 1996 Sep; 56(17):3883-5. PubMed ID: 8752151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical evaluation of chemotherapeutic agents in the treatment of primary liver cancer].
    Ohya T; Kikuchi S
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1623-7. PubMed ID: 6191720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of hepatocellular carcinoma with adriamycin. Phase II clinical trial].
    Barbare JC; Ballet F; Petit J; Poupon R; Darnis F
    Gastroenterol Clin Biol; 1984; 8(8-9):679-80. PubMed ID: 6092187
    [No Abstract]   [Full Text] [Related]  

  • 30. [The effect of etoposide (Et) on primary hepatocellular carcinoma].
    Tanaka N; Furusawa A; Shimoda A; Hirai N; Unoura M; Kato Y; Kobayashi K; Izumi R; Matsui O; Hattori N
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2583-5. PubMed ID: 3039924
    [No Abstract]   [Full Text] [Related]  

  • 31. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma.
    Gelmann EP
    Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-65-S1-70. PubMed ID: 9045318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Investigating the alpha-1-fetoprotein in the blood stream of patients with primary hepatocellular carcinoma in the course of chemotherapy (author's transl)].
    Zizkovský V; Kordac V; Masek Z; Stĕpán J; Korcáková J; Blahníková L
    Cesk Gastroenterol Vyz; 1980 Oct; 34(7):465-73. PubMed ID: 6160917
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
    Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
    Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors.
    Villa E; Ferretti I; Grottola A; Buttafoco P; Buono MG; Giannini F; Manno M; Bertani H; Dugani A; Manenti F
    Br J Cancer; 2001 Apr; 84(7):881-5. PubMed ID: 11286465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does hepatitis B viral load determine the outcome of patients with hepatocellular carcinoma undergoing chemotherapy?
    Huo TI; Wu JC; Lee SD
    Hepatology; 2007 Nov; 46(5):1665-6; author reply 1666. PubMed ID: 17969038
    [No Abstract]   [Full Text] [Related]  

  • 36. Response of a hepatocellular carcinoma to the cisplatin-vinblastine-bleomycin drug regimen.
    Schottinger J; Armentrout S; Slater L; Liao S; McClendon J; Recher L
    Cancer Treat Rep; 1984 Nov; 68(11):1419-20. PubMed ID: 6209009
    [No Abstract]   [Full Text] [Related]  

  • 37. Combination chemotherapy with anticancer agents and OK-432.
    Kimura I; Onoshi T; Takano J; Osawa H; Yasuhara S
    Acta Med Okayama; 1974 Dec; 28(6):411-21. PubMed ID: 4142360
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: a Southeastern Cancer Study Group Trial.
    Ravry MJ; Omura GA; Bartolucci AA; Einhorn L; Kramer B; Davila E
    Cancer Treat Rep; 1986 Feb; 70(2):311-2. PubMed ID: 3004729
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase II trial of m-AMSA in hepatocellular carcinoma: a Southwest Oncology Group Study.
    Bukowski RM; Legha S; Saiki J; Eyre HJ; O'Bryan R
    Cancer Treat Rep; 1982 Aug; 66(8):1651-2. PubMed ID: 6286120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trial of adriamycin in primary hepatocellular carcinoma.
    Tsega E
    Ethiop Med J; 1984 Jan; 22(1):55-9. PubMed ID: 6317377
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.